LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Health & Fitness
• Education
• Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, article, irinotecan, gastric, advanced, pubmed, google, scholar, cas, treatment, phase, trial, thirdline, patients, monotherapy, versus, iii, chemotherapy, study, oncol, dois, randomised, survival, privacy, cookies, content, data, yasui, shizuoka, refractory, access, cisplatin, lancet, information, publish, research, search, august, machida, clinical, platinum, therapy, secondline, eur, doijejca, randomized, clin, doijco, adenocarcinoma, treated,

Topics {✒️}

org/professionals/physician_gls/pdf/gastric month download article/chapter treatment-related deaths occurred tcog gi-0801/birip trial prior combination chemotherapy gastro-oesophageal junction adenocarcinoma article cancer chemotherapy phase iii trial median survival time full article pdf japanese clinical practice chemotherapy-refractory advanced related subjects fluorouracil versus combination advanced gastric cancer heavily treated advanced privacy choices/manage cookies irinotecan therapy pretreated gastric cancer subsequent therapy measurable disease metastatic gastric cancer oncology gastric cancer refractory oesophagogastric adenocarcinoma european economic area anti-tumor effect arbeitsgemeinschaft internistische onkologie severe peritoneal metastasis revised recist guideline ethics declarations conflict article kawakami shizuoka cancer center conditions privacy policy optimal dose modification cisplatin versus irinotecan paclitaxel versus placebo information department moh phase 3 trial cisplatin versus s-1 salvage chemotherapy accepting optional cookies response evaluation criteria main content log article log gastric cancer gastric cancer 12 gastric cancer gastric cancer 16 open-label check access

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
         description:Although irinotecan monotherapy is often used in third-line treatment after the failure of taxanes in Japanese clinical practice, its survival benefit is still unclear. The aim of this study is to investigate the efficacy and safety of irinotecan monotherapy as third-line treatment. Clinical data from consecutive patients in whom irinotecan had been initiated as third-line treatment between December 2003 and July 2015 in Shizuoka Cancer Center were retrospectively analyzed. Patients who were refractory or intolerant to fluoropyrimidine with or without platinum in first-line treatment and subsequent therapy with taxanes were included in this study. Irinotecan was administered at 150 mg/m2 every 2 weeks. The data of 50 patients who met the inclusion criteria were analyzed. The overall response rate was 18.4 % (7/38) among the patients with measurable disease. The median progression-free survival time was 66 days, and the median survival time was 180 days from the initiation of irinotecan therapy. The major grade 3 or 4 adverse events including neutropenia, fatigue, and anorexia were observed in 12 (24 %), 8 (16 %), and 7 (14 %), respectively. No treatment-related deaths occurred. Thirteen patients (26 %) required a dose reduction to 120 mg/m2 or less from the initiation of irinotecan. This study suggests that irinotecan as third-line treatment has an anti-tumor effect and is feasible with optimal dose modification for advanced gastric cancer.
         datePublished:2016-08-26T00:00:00Z
         dateModified:2016-08-26T00:00:00Z
         pageStart:809
         pageEnd:814
         sameAs:https://doi.org/10.1007/s00280-016-3138-z
         keywords:
            Advanced gastric cancer
            Irinotecan
            Third-line treatment
            Salvage line
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-016-3138-z/MediaObjects/280_2016_3138_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-016-3138-z/MediaObjects/280_2016_3138_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-016-3138-z/MediaObjects/280_2016_3138_Fig3_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:78
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Takeshi Kawakami
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nozomu Machida
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Hirofumi Yasui
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masahiro Kawahira
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sadayuki Kawai
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yosuke Kito
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yukio Yoshida
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Satoshi Hamauchi
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Takahiro Tsushima
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Akiko Todaka
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tomoya Yokota
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kentaro Yamazaki
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Akira Fukutomi
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yusuke Onozawa
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Department of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
      description:Although irinotecan monotherapy is often used in third-line treatment after the failure of taxanes in Japanese clinical practice, its survival benefit is still unclear. The aim of this study is to investigate the efficacy and safety of irinotecan monotherapy as third-line treatment. Clinical data from consecutive patients in whom irinotecan had been initiated as third-line treatment between December 2003 and July 2015 in Shizuoka Cancer Center were retrospectively analyzed. Patients who were refractory or intolerant to fluoropyrimidine with or without platinum in first-line treatment and subsequent therapy with taxanes were included in this study. Irinotecan was administered at 150 mg/m2 every 2 weeks. The data of 50 patients who met the inclusion criteria were analyzed. The overall response rate was 18.4 % (7/38) among the patients with measurable disease. The median progression-free survival time was 66 days, and the median survival time was 180 days from the initiation of irinotecan therapy. The major grade 3 or 4 adverse events including neutropenia, fatigue, and anorexia were observed in 12 (24 %), 8 (16 %), and 7 (14 %), respectively. No treatment-related deaths occurred. Thirteen patients (26 %) required a dose reduction to 120 mg/m2 or less from the initiation of irinotecan. This study suggests that irinotecan as third-line treatment has an anti-tumor effect and is feasible with optimal dose modification for advanced gastric cancer.
      datePublished:2016-08-26T00:00:00Z
      dateModified:2016-08-26T00:00:00Z
      pageStart:809
      pageEnd:814
      sameAs:https://doi.org/10.1007/s00280-016-3138-z
      keywords:
         Advanced gastric cancer
         Irinotecan
         Third-line treatment
         Salvage line
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-016-3138-z/MediaObjects/280_2016_3138_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-016-3138-z/MediaObjects/280_2016_3138_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-016-3138-z/MediaObjects/280_2016_3138_Fig3_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:78
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Takeshi Kawakami
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nozomu Machida
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Hirofumi Yasui
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masahiro Kawahira
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sadayuki Kawai
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yosuke Kito
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yukio Yoshida
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Satoshi Hamauchi
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Takahiro Tsushima
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Akiko Todaka
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tomoya Yokota
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kentaro Yamazaki
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Akira Fukutomi
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yusuke Onozawa
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Department of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:78
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Department of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Takeshi Kawakami
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Nozomu Machida
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Hirofumi Yasui
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Masahiro Kawahira
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Sadayuki Kawai
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Yosuke Kito
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Yukio Yoshida
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Satoshi Hamauchi
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Takahiro Tsushima
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Akiko Todaka
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Tomoya Yokota
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Kentaro Yamazaki
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Akira Fukutomi
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
               type:PostalAddress
            type:Organization
      name:Yusuke Onozawa
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Department of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagizumi-Cho, Japan
      name:Department of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(118)

• What's the income generated by https://www.springernature.com/gp/authors each month?
• Get to know https://link.springernature.com/home/'s earnings
• How much revenue does https://order.springer.com/public/cart bring in?
• Earnings of https://submission.springernature.com/new-submission/280/3
• How much profit does https://www.springernature.com/gp/librarians/licensing/agc/journals make?
• http://globocan.iarc.fr's financial summary
• What's the revenue for http://www.mhlwgojp/Accessed?
• What's the total monthly financial gain of https://doi.org/10.1016/s1470-2045(08)70035-4?
• https://doi.org/10.1016%2FS1470-2045%2808%2970035-4's total income per month
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18282805 is on a monthly basis
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=S-1%20plus%20cisplatin%20versus%20S-1%20alone%20for%20first-line%20treatment%20of%20advanced%20gastric%20cancer%20%28SPIRITS%20trial%29%3A%20a%20phase%20III%20trial&journal=Lancet%20Oncol&doi=10.1016%2Fs1470-2045%2808%2970035-4&volume=9&pages=215-221&publication_year=2008&author=Koizumi%2CW&author=Narahara%2CH&author=Hara%2CT?
• Monthly income for https://doi.org/10.1016/s1470-2045(09)70259-1
• How much does https://doi.org/10.1016%2FS1470-2045%2809%2970259-1 bring in each month?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19818685 produce monthly?
• Get to know http://scholar.google.com/scholar_lookup?&title=Fluorouracil%20versus%20combination%20of%20irinotecan%20plus%20cisplatin%20versus%20S-1%20in%20metastatic%20gastric%20cancer%3A%20a%20randomised%20phase%203%20study&journal=Lancet%20Oncol&doi=10.1016%2Fs1470-2045%2809%2970259-1&volume=10&pages=1063-1069&publication_year=2009&author=Boku%2CN&author=Yamamoto%2CS&author=Fukuda%2CH's earnings
• How much revenue does https://doi.org/10.1016/j.ejca.2011.06.002 produce monthly?
• What's the income generated by https://doi.org/10.1016%2Fj.ejca.2011.06.002 each month?
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21742485?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Survival%20advantage%20for%20irinotecan%20versus%20best%20supportive%20care%20as%20second-line%20chemotherapy%20in%20gastric%20cancer%E2%80%93a%20randomised%20phase%20III%20study%20of%20the%20Arbeitsgemeinschaft%20Internistische%20Onkologie%20%28AIO%29&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2011.06.002&volume=47&pages=2306-2314&publication_year=2011&author=Thuss-Patience%2CPC&author=Kretzschmar%2CA&author=Bichev%2CD?
• Check the income stats for https://doi.org/10.1200/jco.2011.39.4585
• Get to know https://doi.org/10.1200%2FJCO.2011.39.4585's earnings
• How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22412140 have monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Salvage%20chemotherapy%20for%20pretreated%20gastric%20cancer%3A%20a%20randomized%20phase%20III%20trial%20comparing%20chemotherapy%20plus%20best%20supportive%20care%20with%20best%20supportive%20care%20alone&journal=J%20Clin%20Oncol&doi=10.1200%2Fjco.2011.39.4585&volume=30&pages=1513-1518&publication_year=2012&author=Kang%2CJH&author=Lee%2CSI&author=Lim%20do%2CH net monthly?
• How much does https://doi.org/10.1016/s1470-2045(13)70549-7 bring in each month?
• Revenue of https://doi.org/10.1016%2FS1470-2045%2813%2970549-7
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24332238 make?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Docetaxel%20versus%20active%20symptom%20control%20for%20refractory%20oesophagogastric%20adenocarcinoma%20%28COUGAR-02%29%3A%20an%20open-label%2C%20phase%203%20randomised%20controlled%20trial&journal=Lancet%20Oncol&doi=10.1016%2Fs1470-2045%2813%2970549-7&volume=15&pages=78-86&publication_year=2014&author=Ford%2CHE&author=Marshall%2CA&author=Bridgewater%2CJA produce monthly?
• How much does https://doi.org/10.1016/s0140-6736(13)61719-5 rake in every month?
• How much does https://doi.org/10.1016%2FS0140-6736%2813%2961719-5 bring in each month?
• How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24094768 making per month?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Ramucirumab%20monotherapy%20for%20previously%20treated%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20adenocarcinoma%20%28REGARD%29%3A%20an%20international%2C%20randomised%2C%20multicentre%2C%20placebo-controlled%2C%20phase%203%20trial&journal=Lancet&doi=10.1016%2Fs0140-6736%2813%2961719-5&volume=383&pages=31-39&publication_year=2014&author=Fuchs%2CCS&author=Tomasek%2CJ&author=Yong%2CCJ?
• https://doi.org/10.1200/jco.2012.48.5805's total income per month
• Revenue of https://doi.org/10.1200%2FJCO.2012.48.5805
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24190112?
• What's http://scholar.google.com/scholar_lookup?&title=Randomized%2C%20open-label%2C%20phase%20III%20study%20comparing%20irinotecan%20with%20paclitaxel%20in%20patients%20with%20advanced%20gastric%20cancer%20without%20severe%20peritoneal%20metastasis%20after%20failure%20of%20prior%20combination%20chemotherapy%20using%20fluoropyrimidine%20plus%20platinum%3A%20WJOG%204007%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2Fjco.2012.48.5805&volume=31&pages=4438-4444&publication_year=2013&author=Hironaka%2CS&author=Ueda%2CS&author=Yasui%2CH's gross income?
• What's the monthly income of https://doi.org/10.1016/s1470-2045(14)70420-6?
• How much revenue does https://doi.org/10.1016%2FS1470-2045%2814%2970420-6 bring in?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25240821 pull in monthly?
• Get to know http://scholar.google.com/scholar_lookup?&title=Ramucirumab%20plus%20paclitaxel%20versus%20placebo%20plus%20paclitaxel%20in%20patients%20with%20previously%20treated%20advanced%20gastric%20or%20gastro-oesophageal%20junction%20adenocarcinoma%20%28RAINBOW%29%3A%20a%20double-blind%2C%20randomised%20phase%203%20trial&journal=Lancet%20Oncol&doi=10.1016%2Fs1470-2045%2814%2970420-6&volume=15&pages=1224-1235&publication_year=2014&author=Wilke%2CH&author=Muro%2CK&author=Cutsem%2CE's earnings
• Financial intake of http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf
• Monthly income for https://doi.org/10.1016/j.ejca.2008.10.026
• How much does https://doi.org/10.1016%2Fj.ejca.2008.10.026 rake in every month?
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19097774
• How much revenue does http://scholar.google.com/scholar_lookup?&title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2008.10.026&volume=45&pages=228-247&publication_year=2009&author=Eisenhauer%2CEA&author=Therasse%2CP&author=Bogaerts%2CJ generate?
• What is the earnings of https://doi.org/10.1038/bmt.2012.244?
• Monthly income for https://doi.org/10.1038%2Fbmt.2012.244
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23208313?
• http://scholar.google.com/scholar_lookup?&title=Investigation%20of%20the%20freely%20available%20easy-to-use%20software%20%E2%80%98EZR%E2%80%99%20for%20medical%20statistics&journal=Bone%20Marrow%20Transplant&doi=10.1038%2Fbmt.2012.244&volume=48&pages=452-458&publication_year=2013&author=Kanda%2CY income
• What are the earnings of https://doi.org/10.1007/s10120-009-0524-9?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20047125 income
• Earnings of http://scholar.google.com/scholar_lookup?&title=Weekly%20paclitaxel%20for%20heavily%20treated%20advanced%20or%20recurrent%20gastric%20cancer%20refractory%20to%20fluorouracil%2C%20irinotecan%2C%20and%20cisplatin&journal=Gastric%20Cancer&doi=10.1007%2Fs10120-009-0524-9&volume=12&pages=206-211&publication_year=2009&author=Shimoyama%2CR&author=Yasui%2CH&author=Boku%2CN
• What's the income of https://doi.org/10.1200/jco.2015.63.5995?
• What's the financial intake of https://doi.org/10.1200%2FJCO.2015.63.5995?
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26884585?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%20Phase%20III%20Trial%20of%20Apatinib%20in%20Patients%20With%20Chemotherapy-Refractory%20Advanced%20or%20Metastatic%20Adenocarcinoma%20of%20the%20Stomach%20or%20Gastroesophageal%20Junction&journal=J%20Clin%20Oncol&doi=10.1200%2Fjco.2015.63.5995&volume=34&pages=1448-1454&publication_year=2016&author=Li%2CJ&author=Qin%2CS&author=Xu%2CJ produce monthly?
• Find out how much https://doi.org/10.1007/s10120-012-0227-5 earns monthly
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23266882's total income per month
• How much does http://scholar.google.com/scholar_lookup?&title=Irinotecan%20combined%20with%205-fluorouracil%20and%20leucovorin%20third-line%20chemotherapy%20after%20failure%20of%20fluoropyrimidine%2C%20platinum%2C%20and%20taxane%20in%20gastric%20cancer%3A%20treatment%20outcomes%20and%20a%20prognostic%20model%20to%20predict%20survival&journal=Gastric%20Cancer&doi=10.1007%2Fs10120-012-0227-5&volume=16&pages=581-589&publication_year=2013&author=Kang%2CEJ&author=Im%2CSA&author=Oh%2CDY rake in every month?
• How much profit is https://doi.org/10.1016/j.ejca.2014.01.020 making per month?
• Learn about the earnings of https://doi.org/10.1016%2Fj.ejca.2014.01.020
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24560487 pull in?
• How much income is http://scholar.google.com/scholar_lookup?&title=Biweekly%20irinotecan%20plus%20cisplatin%20versus%20irinotecan%20alone%20as%20second-line%20treatment%20for%20advanced%20gastric%20cancer%3A%20a%20randomised%20phase%20III%20trial%20%28TCOG%20GI-0801%2FBIRIP%20trial%29&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2014.01.020&volume=50&pages=1437-1445&publication_year=2014&author=Higuchi%2CK&author=Tanabe%2CS&author=Shimada%2CK earning monthly?
• What's the income generated by https://doi.org/10.1016/j.ejca.2015.02.009 each month?
• What's the financial outcome of https://doi.org/10.1016%2Fj.ejca.2015.02.009?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25797356?
• How much money does http://scholar.google.com/scholar_lookup?&title=Randomised%20phase%20III%20trial%20of%20second-line%20irinotecan%20plus%20cisplatin%20versus%20irinotecan%20alone%20in%20patients%20with%20advanced%20gastric%20cancer%20refractory%20to%20S-1%20monotherapy%3A%20TRICS%20trial&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2015.02.009&volume=51&pages=808-816&publication_year=2015&author=Nishikawa%2CK&author=Fujitani%2CK&author=Inagaki%2CH make?
• How much revenue does https://doi.org/10.1200/jco.2012.48.3552 generate?
• How much does https://doi.org/10.1200%2FJCO.2012.48.3552 pull in?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24043745 produce monthly?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Everolimus%20for%20previously%20treated%20advanced%20gastric%20cancer%3A%20results%20of%20the%20randomized%2C%20double-blind%2C%20phase%20III%20GRANITE-1%20study&journal=J%20Clin%20Oncol&doi=10.1200%2Fjco.2012.48.3552&volume=31&pages=3935-3943&publication_year=2013&author=Ohtsu%2CA&author=Ajani%2CJA&author=Bai%2CYX?
• https://citation-needed.springer.com/v2/references/10.1007/s00280-016-3138-z?format=refman&flavour=references's financial summary
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Takeshi%20Kawakami gross monthly?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Takeshi%20Kawakami%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
• Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Nozomu%20Machida
• Get to know https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Nozomu%20Machida%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's earnings
• How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hirofumi%20Yasui generate?
• What's the total monthly financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hirofumi%20Yasui%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masahiro%20Kawahira net monthly?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masahiro%20Kawahira%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
• How profitable is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sadayuki%20Kawai?
• What's the revenue for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sadayuki%20Kawai%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much income is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yosuke%20Kito earning monthly?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yosuke%20Kito%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
• What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yukio%20Yoshida?
• What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yukio%20Yoshida%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What are the total earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Satoshi%20Hamauchi?
• What's the income generated by https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Satoshi%20Hamauchi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en each month?
• What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Takahiro%20Tsushima?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Takahiro%20Tsushima%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en rake in every month?
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Akiko%20Todaka income
• Financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Akiko%20Todaka%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Monthly income for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tomoya%20Yokota
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tomoya%20Yokota%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
• How much income does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kentaro%20Yamazaki have?
• See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kentaro%20Yamazaki%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Akira%20Fukutomi's financial summary
• Profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Akira%20Fukutomi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What is the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yusuke%20Onozawa?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yusuke%20Onozawa%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
• How profitable is https://s100.copyright.com/AppDispatchServlet?title=Efficacy%20and%20safety%20of%20irinotecan%20monotherapy%20as%20third-line%20treatment%20for%20advanced%20gastric%20cancer&author=Takeshi%20Kawakami%20et%20al&contentID=10.1007%2Fs00280-016-3138-z©right=Springer-Verlag%20Berlin%20Heidelberg&publication=0344-5704&publicationDate=2016-08-26&publisherName=SpringerNature&orderBeanReset=true?
• How much does https://crossmark.crossref.org/dialog/?doi=10.1007/s00280-016-3138-z generate monthly?
• What's the financial gain of https://citation-needed.springer.com/v2/references/10.1007/s00280-016-3138-z?format=refman&flavour=citation?
• What are the total earnings of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
• How much does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research earn?
• What's the income of https://www.springernature.com/gp/products?
• What's the revenue for https://www.springernature.com/gp/librarians?
• How much does https://www.springernature.com/gp/societies make?
• What's the total monthly financial gain of https://www.springernature.com/gp/partners?
• Financial intake of https://www.springer.com/
• Learn how profitable https://www.nature.com/ is on a monthly basis
• How much revenue does https://www.biomedcentral.com/ generate?
• What's the income generated by https://www.palgrave.com/ each month?
• Income figures for https://www.apress.com/
• What's the financial gain of https://www.springernature.com/gp/legal/ccpa?
• Learn about the earnings of https://www.springernature.com/gp/info/accessibility
• Learn about the earnings of https://support.springernature.com/en/support/home
• How much profit does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations make?
• What's the total monthly financial gain of https://www.springernature.com/?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref